Log In
Friday 25th May 2018

Over-the-counter obesity drug

14th June 2007

The UK-based pharmaceutical group GlaxoSmithKline’s weight control drug Alli has been moved from prescription to over-the-counter sales in the US.

It is the first weight control drug to make the switch and is designed to tap into the large and growing concern about obesity.

The drug will be sold in pharmacies and other outlets for about $55 a month but will be closely linked to an advertising campaign that stresses it should only be used in conjunction with weight loss programmes. Alli is also to be filed for regulatory approval in Europe.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based applications for healthcare
© Mayden Foundation 2018